A New Model for Funding Cost-Effectiveness Research
Powered by science, centered on people, designed to save.
Public Good Pharma helps payers and self-insured employers cut through the barriers that keep drug costs high.
Unlike traditional Pharma, PGP is motivated to prove low-cost alternatives, or reduced dosing of specialty drugs can provide equal or better outcomes while reducing your costs.
Public Good Pharma partners with health insurers to design and run self-funding Interventional Pharmacoeconomic (IVPE) trials that compare expensive specialty drugs to lower-cost alternatives, including repurposed generics, biosimilars, dose de-escalations and lifestyle interventions. This model, referred to as a “revolving research fund”, is already being successfully implemented in the Netherlands.
Reduce Financial Toxicity
Improve Patient Outcomes
Established as a social enterprise, our long-term objective is supporting adoption of the most cost-effective therapies that improve access and sustainability. We work with forward-thinking payers aligned with improving the affordability of healthcare, including self-insured employers, pass-through PBMs, state health plans, and integrated health systems.
Connect with us to explore how IVPE trials can guarantee 20% cost-savings per patient during IVPE trials with likelihood of 50-90% cost-savings on the most expensive speciality drugs on your health plan, including cell & gene therapies.
